SSA
AUTL

Sierra Summit Advisors’s Autolus Therapeutics AUTL Stock Holding History

Sierra Summit Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-42,744
Closed -$275K – 153
2023
Q4 		$275K Buy
+42,744
New +$163K 0.08% 145

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sierra Summit Advisors's AUTL Position: Q1 2024 in Review

Sierra Summit Advisors sold out of Autolus Therapeutics (AUTL) in Q1 2024, closing a stake of 42,744 shares — an estimated $275K sold.

Sierra Summit Advisors first reported a position in AUTL in Q4 2023 and held it in 1 quarter. The position peaked at $275K in Q4 2023. 121 funds tracked by Wall St. Rank hold AUTL as of Q1 2024.

  • Sierra Summit Advisors reported no remaining Autolus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Sierra Summit Advisors sold 42,744 Autolus Therapeutics shares in Q1 2024, an estimated $275K.
  • Sierra Summit Advisors first reported a position in Autolus Therapeutics in Q4 2023 and held it in 1 quarter.
  • Sierra Summit Advisors's Autolus Therapeutics position peaked at $275K in Q4 2023.
  • 121 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2024.

Based on Sierra Summit Advisors's 13F filing for Q1 2024, filed 9 May 2024.